These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15706428)

  • 1. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.
    Aas T; Geisler S; Helle H; Børresen-Dale AL; Lønning PE; Akslen LA
    Oncol Rep; 2005 Mar; 13(3):525-30. PubMed ID: 15706428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
    Faneyte IF; Schrama JG; Peterse JL; Remijnse PL; Rodenhuis S; van de Vijver MJ
    Br J Cancer; 2003 Feb; 88(3):406-12. PubMed ID: 12569384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer.
    Arriola E; Moreno A; Varela M; Serra JM; Falo C; Benito E; Escobedo AP
    Eur J Cancer; 2006 Nov; 42(17):2954-60. PubMed ID: 16935488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
    Lee J; Im YH; Lee SH; Cho EY; Choi YL; Ko YH; Kim JH; Nam SJ; Kim HJ; Ahn JS; Park YS; Lim HY; Han BK; Yang JH
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):569-77. PubMed ID: 17508214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Aas T; Geisler S; Eide GE; Haugen DF; Varhaug JE; Bassøe AM; Thorsen T; Berntsen H; Børresen-Dale AL; Akslen LA; Lønning PE
    Eur J Cancer; 2003 Mar; 39(4):438-46. PubMed ID: 12751373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.
    Vincent-Salomon A; Rousseau A; Jouve M; Beuzeboc P; Sigal-Zafrani B; Fréneaux P; Rosty C; Nos C; Campana F; Klijanienko J; Al Ghuzlan A; Sastre-Garau X;
    Eur J Cancer; 2004 Jul; 40(10):1502-8. PubMed ID: 15196533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
    Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
    Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
    Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
    J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
    Stefansson IM; Salvesen HB; Immervoll H; Akslen LA
    Histopathology; 2004 May; 44(5):472-9. PubMed ID: 15139995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas.
    Szczuraszek K; Mazur G; Jeleń M; Dziegiel P; Surowiak P; Zabel M
    Anticancer Res; 2008; 28(2A):1113-8. PubMed ID: 18507062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA
    Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.
    Penault-Llorca F; Abrial C; Raoelfils I; Chollet P; Cayre A; Mouret-Reynier MA; Thivat E; Mishellany F; Gimbergues P; Durando X
    Oncologist; 2008 Dec; 13(12):1235-45. PubMed ID: 19091781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
    Jung SY; Han W; Lee JW; Ko E; Kim E; Yu JH; Moon HG; Park IA; Oh DY; Im SA; Kim TY; Hwang KT; Kim SW; Noh DY
    Ann Surg Oncol; 2009 May; 16(5):1112-21. PubMed ID: 19219507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade.
    Nakamura N; Yamamoto H; Yao T; Oda Y; Nishiyama K; Imamura M; Yamada T; Nawata H; Tsuneyoshi M
    Hum Pathol; 2005 Jul; 36(7):828-37. PubMed ID: 16084954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.